Abstract Number: 1649 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Background/Purpose: Olokizumab (OKZ) is a humanized anti-interleukin-6 monoclonal antibody in development for moderate-to-severe rheumatoid arthritis (RA) treatment. OKZ efficacy and safety were assessed in the…Abstract Number: 1650 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy in Early Rheumatoid Arthritis: Data from Two Phase 3 Randomized Controlled Trials
Background/Purpose: Disease remission is the current treatment goal for patients (pts) with early RA (eRA). Initiation of an anti-TNF agent ± methotrexate (MTX) is recommended…Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…Abstract Number: 1652 • 2015 ACR/ARHP Annual Meeting
A HPLC-SRM-MS Based Method for the Detection of Adherence to Low-Dose Oral Methotrexate
Background/Purpose: Whilst methotrexate (MTX) is the first-line treatment of rheumatoid arthritis (RA), response is not universal. Rates of adherence reported in the literature range from…Abstract Number: 1653 • 2015 ACR/ARHP Annual Meeting
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis
Background/Purpose: There is a growing emphasis on treating patients to a target level of low disease activity (LDA) or remission to order to improve outcomes…Abstract Number: 1654 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Background/Purpose: Several published randomized head-to-head trials in rheumatoid arthritis (RA) have compared TNFi-MTX with triple therapy (MTX + hydroxychloroquine + sulfasalazine) in MTX-naive patients (MTX-Ns)…Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…Abstract Number: 1657 • 2015 ACR/ARHP Annual Meeting
Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study
Background/Purpose: In patients with early RA, autoantibodies, elevated MMP-3, and acute phase proteins are prognostic biomarkers of joint damage and disease activity. However, the ability…Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…Abstract Number: 1659 • 2015 ACR/ARHP Annual Meeting
Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Background/Purpose: It is recommended that all patients receiving MTX also receive at least 5mg/week of folic acid in an effort to reduce occurrence of MTX…Abstract Number: 1660 • 2015 ACR/ARHP Annual Meeting
Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy
Background/Purpose: Dose reduction of biological therapy in patients with chronic arthritis (CA) with good clinical response is a common pattern in clinical practice. However, most…Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting
Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…Abstract Number: 1662 • 2015 ACR/ARHP Annual Meeting
Treat to Target of Remission Is Effective but Not All Patients Are Always in Remission
Background/Purpose: Presently the goals of rheumatoid arthritis (RA) therapy are to control symptoms, to prevent joint damage and disability. Attaining long-term clinical remission or at…Abstract Number: 1663 • 2015 ACR/ARHP Annual Meeting
Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining clinical efficacy and a rapid onset of action with a good safety profile…
ACR Meeting Abstracts